Clinical Trial Update: To Determine the Maximum Tolerated Dose (MTD) of BIBF 1120 in Patients With Solid Tumours [Phase 1]

View source ↗

Summary

Phase 1 trial to determine the maximum tolerated dose of BIBF 1120 in patients with malignant solid tumors has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumor

Drugs mentioned

• BIBF 1120 (nintedanib)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Malignant Solid Tumour | Phase 1 | Status: COMPLETED